Severity of coeliac disease and clinical management study when using a non-metabolised medication: a phase I pharmacokinetic study

OBJECTIVE: The non-metabolised antihistamine fexofenadine has oral absorption resulting from transporter activity. Uptake by enterocyte organic anion transporting polypeptides and efflux by an ATP-binding cassette transporter (P-glycoprotein) are primary determinants. Coeliac disease-mediated lesion...

Descripción completa

Detalles Bibliográficos
Autores principales: Chretien, Marc L, Bailey, David G, Asher, Linda, Parfitt, Jeremy, Driman, David, Gregor, Jamie, Dresser, George K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Pharmacology and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972437/
https://www.ncbi.nlm.nih.gov/pubmed/36828648
http://dx.doi.org/10.1136/bmjopen-2021-057151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972437/
https://www.ncbi.nlm.nih.gov/pubmed/36828648
http://dx.doi.org/10.1136/bmjopen-2021-057151

Ejemplares similares